GLP-3: The Next Generation
"GLP-3" is an informal term for retatrutide, an investigational triple agonist. Retatrutide is investigational and not FDA-approved. This is general education; GLP3 Weight Loss does not prescribe, dispense, treat, or arrange access to retatrutide.
What Makes GLP-3 Different
- Triple Mechanism: Targets GLP-1 + GIP + glucagon receptors simultaneously
- Investigational: Not FDA-approved; remains in clinical trials
- Increased Energy Expenditure: Glucagon activation is associated in trials with more calories burned at rest
- Enhanced Fat Oxidation: Associated in trials with increased hepatic fat oxidation
Clinical Results
A Phase 2 trial published in the New England Journal of Medicine (2023) reported about 24% average body weight loss at 48 weeks at the highest dose. These figures describe what researchers observed in that trial — not results we offer, promise, or provide.